Our top pick for
Building a portfolio
Fulcrum Therapeutics, Inc is a biotechnology business based in the US. Fulcrum Therapeutics shares (FULC) are listed on the NASDAQ and all prices are listed in US Dollars. Fulcrum Therapeutics employs 73 staff and has a trailing 12-month revenue of around USD$8.8 million.
|52-week range||USD$7.01 - USD$22.39|
|50-day moving average||USD$12.4777|
|200-day moving average||USD$11.5951|
|Wall St. target price||USD$19|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-50.401|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Fulcrum Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Fulcrum Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Fulcrum Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 267x. In other words, Fulcrum Therapeutics shares trade at around 267x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
|Revenue TTM||USD$8.8 million|
|Gross profit TTM||USD$-46,839,000|
|Return on assets TTM||-37.3%|
|Return on equity TTM||-77.68%|
|Market capitalisation||USD$386.8 million|
TTM: trailing 12 months
There are currently 704,988 Fulcrum Therapeutics shares held short by investors – that's known as Fulcrum Therapeutics's "short interest". This figure is 2% up from 690,946 last month.
There are a few different ways that this level of interest in shorting Fulcrum Therapeutics shares can be evaluated.
Fulcrum Therapeutics's "short interest ratio" (SIR) is the quantity of Fulcrum Therapeutics shares currently shorted divided by the average quantity of Fulcrum Therapeutics shares traded daily (recently around 106333.03167421). Fulcrum Therapeutics's SIR currently stands at 6.63. In other words for every 100,000 Fulcrum Therapeutics shares traded daily on the market, roughly 6630 shares are currently held short.
However Fulcrum Therapeutics's short interest can also be evaluated against the total number of Fulcrum Therapeutics shares, or, against the total number of tradable Fulcrum Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Fulcrum Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Fulcrum Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.03% of the tradable shares (for every 100,000 tradable Fulcrum Therapeutics shares, roughly 30 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Fulcrum Therapeutics.
Find out more about how you can short Fulcrum Therapeutics stock.
We're not expecting Fulcrum Therapeutics to pay a dividend over the next 12 months.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and ß-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.